CVS explores options including potential break-up, sources say
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Morgan Stanley Reiterates Overweight Rating on CVS Health (CVS)
October 2, 2024 6:56 AM EDTMorgan Stanley analyst Erin Wright reiterated an Overweight rating and $65.00 price target on CVS Health (NYSE: CVS).
The analyst comments "Latest Hypothetical SOTP Suggests Upside, But Variables Remain: In light of a recent Reuters report (here) noting that the CVS Board may be considering potential options to break up CVS retail and insurance businesses, we detail our latest SOTP analysis, including key assumptions below. CVS declined to... More
Leerink Partners Reiterates Market Perform Rating on CVS Health (CVS)
October 1, 2024 6:28 AM EDTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating on CVS Health (NYSE: CVS).
The analyst comments "Bottom Line: Following our initial note highlighting the potential of CVS evaluating strategic alternatives including a break-up of the company (Initial CVS note; WSJ report) we wanted to include some quick views on the potential plusses and potential minuses of a breakup. This isn't meant to be comprehensive and is intentionally short form given the fluidity of the reported situation. But we thought it was important to highlight how this... More
Evercore ISI Reiterates Outperform Rating on CVS Health (CVS)
October 1, 2024 5:54 AM EDTEvercore ISI analyst Elizabeth Anderson reiterated an Outperform rating and $62.00 price target on CVS Health (NYSE: CVS).
The analyst comments "What happened? After the market close today, Reuters reported that CVS is exploring options, including a potential break-up of the company to... More
